Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient
Open Access
- 16 February 2015
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Endocrinology
- Vol. 2015 (3), 1-4
- https://doi.org/10.1155/2015/676191
Abstract
SGLT2 inhibitors are only approved for use in adults with type 2 diabetes. However, because SGLT2 inhibitors have a mechanism of action that does not require the presence of endogenous insulin, these drugs should also be efficacious in type 1 diabetes where endogenous insulin production is greatly reduced or absent. Herein, I present five cases which illustrate the benefits of utilizing an SGLT2 inhibitor with type 1 diabetes. In these cases the use of SGLT2 inhibitors resulted not only in better glycemic control in most patients but also in some patients’ less hypoglycemia, weight loss, and decreased doses of insulin. In type 1 diabetesCandida albicansvaginitis and balanitis may occur more frequently than in type 2 diabetes. These cases show that a large randomized clinical trial of SGLT2 inhibitors in type 1 diabetes needs to be performed.Keywords
This publication has 13 references indexed in Scilit:
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept TrialDiabetes Care, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitusCardiovascular Diabetology, 2014
- Canagliflozin: Improving diabetes by making urine sweetCleveland Clinic Journal of Medicine, 2013
- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 DiabetesDiabetes Care, 2013
- Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitusDiabetes, Obesity and Metabolism, 2012
- Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literatureDiabetes, Obesity and Metabolism, 2010
- Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?Endocrine Practice, 2008
- Cellular and Molecular Mechanisms for the Initiation and Progression of β Cell Destruction Resulting from the Collaboration Between Macrophages and T CellsAutoimmunity, 1998
- Prospective Study of Predictors of β-Cell Survival in Type I DiabetesDiabetes, 1988